The abstract mentions peptides targeting various mHTT interactions (InsP3R1, CaM, Caspase-6) but doesn't explain which interactions are most critical or how to prioritize therapeutic targets. Understanding this hierarchy is essential for rational drug design. Gap type: open_question Source paper: Unraveling the Puzzle of Therapeutic Peptides: A Promising Frontier in Huntington's Disease Treatment. (None, None, PMID:38207096)
Landscape Summary: What determines the relative therapeutic efficacy of targeting different mHTT interaction partners? is a 0.76 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What determines the relative therapeutic efficacy of targeting different mHTT interaction partners? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: